RxDoctor Payments Data

Fariborz Nazari Adli, MD

Family Medicine · Baytown, TXNPI 1760577019

Payments from drug & device makers

$25,131in general payments, 2019–2025

Across 1,656 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Bayer$2K
  • Dexcom, Inc.$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$1,2005%
  • Food & beverage$23,65894%
  • Education$1541%
  • Gifts$1190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca102$2,487
AbbVie(2 entities)188$1,908
Lilly USA, LLC125$1,584
Bayer71$1,521
Dexcom, Inc.109$1,309
Biohaven Pharmaceuticals, Inc.8$1,295
Amgen(2 entities)127$1,286
Mannkind Corporation49$1,124
Novo Nordisk87$1,106
Boehringer Ingelheim53$826
GSK81$799
Pfizer57$791
Paratek Pharmaceuticals, Inc.62$788
Merck68$752
Otsuka America Pharmaceutical, Inc.60$701
Medtronic(2 entities)26$634
Kowa Pharmaceuticals America, Inc.29$413
Sunovion Pharmaceuticals Inc.33$392
Astellas Pharma US Inc15$388
Esperion Therapeutics, Inc.29$377
Insulet Corporation20$335
Teva Pharmaceuticals USA, Inc.35$325
Antares Pharma, Inc.19$299
Supernus Pharmaceuticals, Inc.20$294
Johnson & Johnson14$228
Currax Pharmaceuticals LLC17$197
Abbott9$190
Amarin Pharma, Inc.10$183
Exact Sciences6$166
Novartis8$159
Takeda Pharmaceuticals U.S.A., Inc.9$155
Sanofi-aventis U.S. LLC5$138
Eisai Inc.7$120
Endo Pharmaceuticals Inc.7$119
Tandem Diabetes Care, Inc.4$117
Ironwood Pharmaceuticals, Inc6$103
Lundbeck LLC5$96
Phathom Pharmaceuticals, Inc.4$94
Idorsia Pharmaceuticals US Inc5$91
Boston Scientific5$89
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$69
Indivior Inc.3$68
Actelion Pharmaceuticals US, Inc.2$64
Jazz Pharmaceuticals Inc.3$59
Philips North America LLC4$57
Verity Pharmaceuticals Inc.2$51
Redhill Biopharma Inc.3$51
Global Blood Therapeutics, Inc.3$50
Tolmar, Inc.2$49
Arbor Pharmaceuticals, Inc.3$48
Scilex Pharmaceuticals Inc.3$45
Mylan Specialty L.p.1$43
Melinta Therapeutics, LLC3$42
Nabriva Therapeutics, PLC2$38
Masimo Corporation2$38
Cequr Corporation2$35
Globus Medical2$35
ERMI LLC1$34
Biohaven Pharmaceutical Holding Company Ltd.2$34
Cumberland Pharmaceuticals, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,131 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$85,238
Medicare patients
51
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide180$235,792
FarxigaDapagliflozin Propanediol105$86,660
JardianceEmpagliflozin62$73,458
MounjaroTirzepatide53$69,984
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$45,734
RybelsusSemaglutide25$37,680
Repatha SureclickEvolocumab42$35,964
Synjardy XrEmpagliflozin/Metformin Hcl28$32,287
EliquisApixaban27$31,093
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/724$27,471
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt24$22,498
KerendiaFinerenone19$20,728
VraylarCariprazine Hcl13$18,443
VascepaIcosapent Ethyl23$17,503
XareltoRivaroxaban14$15,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,106$279,222224 claims
Boehringer IngelheimJardiance, Synjardy Xr$826$105,74590 claims
AstraZenecaFarxiga$2,487$86,660105 claims
Lilly USA, LLCMounjaro$1,584$69,98453 claims
GSKTrelegy Ellipta, Breo Ellipta$799$51,61465 claims
PfizerEliquis$791$31,09327 claims
MerckBelsomra, Janumet Xr$752$26,86648 claims
BayerKerendia$1,521$20,72819 claims
AbbVieVraylar$1,908$18,44313 claims
Johnson & JohnsonXarelto$228$15,59814 claims
Astellas Pharma US IncMyrbetriq$388$5,94913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Baytown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →